# A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela

Source: https://onco.cc/trials/nct07391657/  
OnCo record `nct07391657` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Daratumumab, Carfilzomib, Dexamethasone in multiple myeloma, run by AstraZeneca, now recruiting.

## Summary

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) is a phase 3 interventional study registered as NCT07391657 by AstraZeneca, with 508 participants planned, started 2026-02-23 and due to reach its primary completion in 2028-06-14. Interventions recorded: AZD0120, Daratumumab, Carfilzomib, Dexamethasone, Bortezomib. Conditions listed: Relapsed Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07391657
- Phase: 3
- Setting: A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CART) Therapy Directed Against BCMA and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma.
- Sponsor: AstraZeneca
- Enrolled: 508

## Sources

- ClinicalTrials.gov NCT07391657: https://clinicaltrials.gov/study/NCT07391657

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [AZD0120](https://onco.cc/drugs/azd0120/), [Bortezomib](https://onco.cc/drugs/bortezomib/), [Carfilzomib](https://onco.cc/drugs/carfilzomib/), [Daratumumab](https://onco.cc/drugs/daratumumab/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Pomalidomide](https://onco.cc/drugs/pomalidomide/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct07391657.json